Dyadic International (NASDAQ:DYAI) Stock Price Passes Below 50 Day Moving Average – Here’s What Happened

Dyadic International, Inc. (NASDAQ:DYAI) shares crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.64 and traded as low as $1.55. Dyadic International shares last traded at $1.58, with a volume of 22,184 shares traded.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a report on Thursday, November 14th.

Dyadic International Stock Down 2.5 %

The stock has a market cap of $46.75 million, a P/E ratio of -6.87 and a beta of 0.89. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.54. The firm’s fifty day moving average is $1.64 and its 200 day moving average is $1.40.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.05 million. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. During the same period in the previous year, the company posted ($0.06) earnings per share. As a group, equities research analysts forecast that Dyadic International, Inc. will post -0.18 EPS for the current year.

Institutional Investors Weigh In On Dyadic International

A hedge fund recently bought a new stake in Dyadic International stock. Inlet Private Wealth LLC bought a new stake in shares of Dyadic International, Inc. (NASDAQ:DYAI) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 30,000 shares of the biotechnology company’s stock, valued at approximately $52,000. Inlet Private Wealth LLC owned about 0.10% of Dyadic International at the end of the most recent reporting period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.